TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17333800
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal tablets
Study: 9452848
Drug: Intrathecal pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal pethidine (40 mg)
Study: 9452848
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (2 ml 0.5%)
Study: 7639022
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous ketamine
Study: 3286166
Drug: Constant insulin
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant insulin infusion (0.175 mU/kg.min)
Study: 3286166
Drug: Pulsatile insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile insulin delivery (2.1 mU/kg at 12-min intervals)
Study: 3286166
Drug: Both constant
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both constant and pulsatile insulin delivery
Study: 10827333
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive (OC) containing ethinyl estradiol 20 microg and 0.1 mg levonorgestrel
Study: 10827333
Drug: Lunelle (injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lunelle (injectable contraceptive containing estradiol cypionate 5 mg and medroxyprogesterone acetate 25 mg)
Study: 1487095
Drug: Linear amplifier
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linear amplifier (condition L)
Study: 2982563
Drug: Low-dose antacid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacid gel (6 X 12 ml/d; neutralisation capacity 120 mmol)
Study: 2982563
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g/d)
Study: 30560740
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment for 6 weeks
Study: 27209068
Drug: Person-centered progressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-centered progressive resistance exercise performed twice a week for 15 weeks
Study: 15752388
Drug: cAAI-guided propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cAAI-guided propofol infusion (Group G, n = 10)
Study: 15752388
Drug: cAAI values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: cAAI values in Group G
Study: 12027841
Drug: Sevoflurane titration
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane titration with A‐line auditory guidance (target auditory evoked potential index of 30+/‐5)
Study: 12027841
Drug: Sevoflurane titration
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane titration clinically (without AEP guidance)
Study: 10439477
Drug: Hypericum preparation
Normalized name: Hypericum oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum preparation standardised to 0.17 mg total hypericin per day (114 patients)
Study: 10439477
Drug: Hypericum preparation
Normalized name: Hypericum oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum preparation standardised to 0.33 mg total hypericin per day (115 patients)
Study: 10439477
Drug: Hypericum preparation
Normalized name: Hypericum oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum preparation standardised to 1 mg total hypericin per day (119 patients)
Study: 7852667
Drug: Azelastine (0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (0.56 mg/day)
Study: 2181434
Drug: Tamoxifen (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (exact dosage not specified)
Study: 2181434
Drug: Placebo (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (exact dosage not specified)
Study: 322794
Drug: Cholestyramine (doubled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (doubled dose)
Study: 12636120
Drug: Peroxide control
Normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroxide control (peroxide gel)
Study: 12636120
Drug: Light control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light control (placebo gel and light)
Study: 10992827
Drug: Metamizol (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol (1.2 g)
Study: 30395050
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 1.49 ± 0.44 g·kg·d for oxidation (Ox)
Study: 30395050
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 1.53 ± 0.32 g·kg·d for net protein balance (NB)
Study: 30395050
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake (0.2-2.9 g·kg·d)
Study: 27618886
Drug: Topical betuline
Normalized name: betulin
DrugBank: Betulin (DB16890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betuline gel (TBG)
Study: 22234041
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement containing n-3 polyunsaturated fatty acids (2 cans/day, 2.02 g eicosapentaenoic acid + 0.92 g docosahexaenoic acid/day)
Study: 22234041
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement containing n-3 polyunsaturated fatty acids
Study: 22234041
Drug: Isocaloric control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric control supplement
Study: 20194829
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (CBGT + phenelzine)
Study: 17322426
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg b/d)
Study: 17322426
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg t.d.s)
Study: 15662518
Drug: Typical antipsychotic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotic drugs
Study: 15662518
Drug: Drug-free patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free patients
Study: 11900994
Drug: Lovastatin (10-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (10-60 mg once-daily doses of a controlled-release formulation)
Study: 9990816
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 500 mg clarithromycin + 2 x 1000 mg amoxicillin + 40 mg pantoprazole/day for 7 days
Study: 9990816
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 500 mg clarithromycin + 2 x 400 mg ranitidine bismuth citrate/day for 14 days
Study: 2181859
Drug: 2.2 g
Normalized name: Vaporizer Safeguard 2.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 g n-3 FAs/d (group 1)
Study: 2181859
Drug: 1.1 g
Normalized name: Giazo 1.1 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 g n-3 FAs/d (group 2)
Study: 30073766
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg once daily for 16 weeks
Study: 8589023
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2) and cisplatin (50 mg/m2)
Study: 7230259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of self-control and cue extinction procedures
Study: 29737099
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg voriconazole tablets
Study: 23071122
Drug: Ramipril (R;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (R; 10 mg daily)
Study: 23071122
Drug: Telmisartan (T;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (T; 80 mg daily)
Study: 23071122
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ramipril and Telmisartan (T+R)
Study: 16896736
Drug: NV (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: NV (no treatment)
Study: 14520020
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice (330 ml/day providing 37.0 mg/day lycopene)
Study: 14520020
Drug: Carrot juice
Normalized name: carrot juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot juice (330 ml/day providing 27.1 mg/day beta-carotene and 13.1 mg/day alpha-carotene)
Study: 7567290
Drug: Cefixime (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (7.5 mg/kg orally twice daily for 14 days)
Study: 7567290
Drug: Ceftriaxone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (50 to 70 mg/kg im once daily for 5 days)
Study: 7567290
Drug: Aztreonam (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (50 to 70 mg/kg im every 8 hours for 7 days)
Study: 2026339
Drug: Hypnotic relaxation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic relaxation period
Study: 31594202
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment applied to trigger points
Study: 31585944
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 800 mg four times daily for five days (total 16 g)
Study: 31585944
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 1000 mg three times daily for 10 days (total 30 g)
Study: 25829811
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg before PCI and for 5 days after PCI
Study: 25829811
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 mg daily after PCI)
Study: 16463053
Drug: Verapamil hydrochloride
Normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil hydrochloride (calcium channel blocker), starting 3 days before SWL and continued for 4 weeks after the procedure
Study: 16463053
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific medication (control group)
Study: 15001941
Drug: Desmopressin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (20-40 microg intranasal) with conditioning alarm therapy
Study: 15001941
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray with conditioning alarm therapy
Study: 7896541
Drug: Cisplatin 14
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 14 mg/m2 daily and 5-fluorouracil 700 mg/m2 daily for 5 days plus alpha-interferon 1 x 10(6) units/m2 daily for five days (phase I)
Study: 7896541
Drug: Cisplatin 17
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 17 mg/m2/day, 5-fluorouracil 700 mg/m2/day and alpha-interferon 3 x 10(6) units/m2/day (phase II)
Study: 28194093
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g whey protein + 2 g amylopectin-chromium complex (WPACr)
Study: 28194093
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g whey protein (WP)
Study: 25242569
Drug: 50-μg transdermal
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-μg transdermal estradiol patch
Study: 24103853
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (LTPP + Fluoxetine)
Study: 20729000
Drug: Arginine Vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine Vasopressin nasal spray (20 IU)
Study: 17175311
Drug: 7 x
Normalized name: TachoSil 3.7 X 1.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 x 10 g IVIG
Study: 17175311
Drug: 7 x
Normalized name: TachoSil 3.7 X 1.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 x 10 g IV albumin
Study: 15041604
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (PCEA; 0.125% ropivacaine plus sufentanil 1 microg/mL at a base rate of 12 mL/h and bolus application of 5 mL/15 min)
Study: 15041604
Drug: Conventional patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional patient-controlled IV analgesia (PCIA; morphine 3 mg/15 min)
Study: 11461124
Drug: Sequential antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential antibiotic therapy (switch therapy)
Study: 9426760
Drug: Tolterodine 1
Normalized name: tolterodine 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 1 mg and 2 mg
Study: 27283779
Drug: Sacubitril/valsartan (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (lower doses: 100/50/0 mg)
Study: 27283779
Drug: Enalapril (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (lower doses: 5/2.5/0 mg)
Study: 27283779
Drug: Any dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any dose reduction (both treatments)
Study: 20649630
Drug: Glimepiride (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (up to 6 mg/day)
Study: 11176977
Drug: Low-dose external
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose external beam irradiation at a dose of 14 Gy in 7 fractions of 2 Gy
Study: 7875272
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 125 micrograms carbachol
Study: 31905341
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg daily dose)
Study: 31905341
Drug: Nonusers (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers (no aspirin)
Study: 29432808
Drug: naloxegol 25
Normalized name: naloxegol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxegol 25 mg once daily
Study: 26911949
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily orally for at least 15 days
Study: 20730091
Drug: Meningococcal serogroup
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal serogroup C conjugate vaccine (MenCC) administered at 14 months of age and catch-up immunization for ages 14 months to 18 years.
Study: 20730091
Drug: Meningococcal serogroup
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal serogroup C conjugate vaccine (MenCC) administered above 5 years of age.
Study: 10807465
Drug: Immunoadsorption (IA)
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoadsorption (IA) and subsequent immunoglobulin G (IgG) substitution
Study: 10807465
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment (Control group)
Study: 1591948
Drug: Allopurinol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (50 mg by mouth 4 times a day)
Study: 1591948
Drug: DMSO (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO (500 mg by mouth 4 times a day)
Study: 27173469
Drug: RVX-208 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVX-208 (100 mg b.i.d. for 29-33 days)
Study: 24815101
Drug: Progestin‐only pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin‐only pills (POPs)
Study: 16281834
Drug: Oral ciprofloxacine
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacine (0.5 g) 90‐120 min before TUR
Study: 16281834
Drug: Intravenous ciprofloxacine
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacine (0.4 g) 30‐60 min before TUR
Study: 16281834
Drug: Routine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotic prophylaxis (control)
Study: 10461844
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g cefuroxime administered intravenously 10 min before surgery
Study: 8594657
Drug: Lobenzarit disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lobenzarit disodium (CCA) in combination with sodium aurothiomalate and D-penicillamine (group-A)
Study: 7369913
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cefaclor
Study: 23252444
Drug: High-frequency physical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency physical therapy
Study: 14701778
Drug: Motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motexafin gadolinium (MGd) 5 mg/kg/d with whole-brain radiation therapy (WBRT) 30 Gy in 10 fractions
Study: 14701778
Drug: Whole-brain radiation
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain radiation therapy (WBRT) 30 Gy in 10 fractions without motexafin gadolinium (MGd)
Study: 9180238
Drug: Lipid-modulating therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-modulating therapy that lowers LDL cholesterol
Study: 9180238
Drug: Lipid-modulating therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-modulating therapy that lowers LDL cholesterol and decreases serum triglyceride and/or increases HDL cholesterol
Study: 27999883
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg in pediatric subjects
Study: 27999883
Drug: Alogliptin 12.5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg in pediatric subjects
Study: 27999883
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg in adults
Study: 16571278
Drug: Jiawei Huangqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiawei Huangqi Guizhi Wuwu Decoction (JHGWD) combined with chemotherapy and oxaliplatin
Study: 11144398
Drug: Cefdinir 14
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 14 mg/kg daily (QD)
Study: 11144398
Drug: Cefdinir 7
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 7 mg/kg twice a day (BID)
Study: 11144398
Drug: Amoxicillin/clavulanate 40/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 40/10 mg/kg/day divided TID
Study: 9225366
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human Interleukin‐3 (rhIL‐3) at doses of 0.5, 1.0, 5.0, 7.5, and 10 micrograms/kg
Study: 9225366
Drug: Control cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cycles (no cytokine therapy)
Study: 9225366
Drug: Cytokine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine treatment (rhIL‐3 and rhGM‐CSF)
Study: 8452175
Drug: Fleroxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (400 mg once a day)
Study: 8452175
Drug: Ceftazidime (0.5‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (0.5‐2 g three times a day or 1‐2 g twice a day)
Study: 3732047
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy in initial treatment
Study: 25885678
Drug: Unused returned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unused returned medication
Study: 25885678
Drug: Plasma nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma nevirapine concentration >100 ng/ml
Study: 25885678
Drug: Missed doses
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missed doses by maternal verbal reports
Study: 20809267
Drug: Selenium-enriched chicken
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-enriched chicken (4 portions of 200 g/week)
Study: 20809267
Drug: Non-enriched chicken
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-enriched chicken (4 portions of 200 g/week)
Study: 17717532
Drug: Sulfurous mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfurous mineral water (500 ml day(‐1) for 2 weeks)
Study: 11419888
Drug: Abciximab bolus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab bolus plus 12-h infusion
Study: 26200146
Drug: 2% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CHX solution for 60 s after acid etching and before adhesive application
Study: 23637033
Drug: Catheter-over-needle group
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-over-needle group (received a second bolus of 20 mL of 0.2% ropivacaine postoperatively)
Study: 23637033
Drug: Single-shot group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot group (received 25-30 mL of 1.5% lidocaine and 0.125% bupivacaine)
Study: 21269402
Drug: Testosterone pellets
Normalized name: testosterone pellets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone pellets (75 mg each, 8 to 12 pellets, total 450 mg to 900 mg)
Study: 18563471
Drug: Reboxetine (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4-6 mg/d)
Study: 18563471
Drug: Methylphenidate (20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (20-50 mg/d)
Study: 17586417
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg/HCTZ 12.5 mg